JAMA Oncology : Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
JAMA Network - Un pódcast de The JAMA Network
Categorías:
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.
Related Content:
